EUVIMEDEUVIMED entdecken
Vergleichsstudie

Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer

Mengmeng Liu, Lu Zhong, Mei Dong, Tong Liu

Expert Review of Pharmacoeconomics & Outcomes Research · 21.04.2026 · 26 (4) · 537-547

DOI: 10.1080/14737167.2026.2642646 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 09.03.2026. Verfasst von Mengmeng Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: the Scientific Research Project of Heilongjiang Provincial Health Commission, Haiyan Foundation of Harbin Medical University Cancer Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsHumansCost-Benefit AnalysisAntibodies, Monoclonal, HumanizedTrastuzumabCost-Effectiveness AnalysisQuinazolinesErb-b2 Receptor Tyrosine KinasesChinaDrug Resistance, NeoplasmPyridinesOxazolesQuality-Adjusted Life YearsModels, EconomicNeoplasm Metastasis

Stichwörter der Autor:innen

Tucatinibcolorectal cancercost-effectivenesspertuzumabpharmacoeconomicstrastuzumab

Substanzen

Antibodies, Monoclonal, HumanizedTrastuzumabtucatinibQuinazolinesErb-b2 Receptor Tyrosine KinasespertuzumabPyridinesOxazolesERBB2 protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China.

Förderung

  • the Scientific Research Project of Heilongjiang Provincial Health Commission
  • Haiyan Foundation of Harbin Medical University Cancer Hospital

Zitieren

APA

Liu, M., Zhong, L., Dong, M., & Liu, T. (2026). Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer. Expert Review of Pharmacoeconomics & Outcomes Research, 26(4), 537-547. https://doi.org/10.1080/14737167.2026.2642646

Vancouver

Liu M, Zhong L, Dong M, Liu T. Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(4):537-547. doi:10.1080/14737167.2026.2642646

BibTeX
@article{Liu2026,
  author = {Liu, Mengmeng and Zhong, Lu and Dong, Mei and Liu, Tong},
  title = {Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2026},
  volume = {26},
  number = {4},
  pages = {537--547},
  doi = {10.1080/14737167.2026.2642646}
}
Kostenlos starten →